Related Experiment Videos
[Pharmacological biomodulation in cancer]
1Laboratorio de Cultivo de Tejidos y Biología de Tumores, Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela, Apartado Postal 47114, Caracas, 1041-A Venezuela.
Abstract:
The discovery of the P-glycoprotein as a mediator of multidrug resistance (MDR) represents one of the most important research accomplishments in antineoplastic pharmacology during the last decade. Demonstration of Pgp in epithelial tissues, untreated and chemotherapeutically pretreated human malignancies, and identification of various agents capable of reversing in vitro resistance has generated enthusiasm for clinical studies throughout the world. This review discusses recent developments of experimental and clinical investigations of MDR reversing agents in cancer.
Insights
P-glycoprotein (Pgp) mediates multidrug resistance (MDR) in cancer. Agents reversing this resistance are being investigated in clinical studies worldwide for improved cancer treatment outcomes.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- P-glycoprotein (Pgp) is a key mediator of multidrug resistance (MDR) in cancer.
- Pgp is present in various human epithelial tissues and malignancies, both untreated and pretreated with chemotherapy.
- The identification of agents that can reverse Pgp-mediated resistance in vitro has spurred significant research interest.
Purpose of the Study:
- To review recent advancements in the experimental and clinical investigation of multidrug resistance reversing agents in cancer therapy.
- To highlight the significance of P-glycoprotein in antineoplastic pharmacology.
Main Methods:
- Review of experimental studies on MDR reversing agents.
- Analysis of clinical investigations involving MDR reversing agents.
- Examination of P-glycoprotein's role in drug resistance.
Main Results:
- P-glycoprotein's discovery is a major breakthrough in cancer pharmacology.
- Demonstration of Pgp in human malignancies and its role in resistance.
- Identification of agents capable of reversing in vitro resistance.
Conclusions:
- Multidrug resistance reversing agents show promise for cancer treatment.
- Further clinical studies are warranted to evaluate the efficacy of these agents.
- Understanding Pgp's role is crucial for overcoming chemotherapy resistance.